aTyr Pharma aligns with FDA on Phase 3 efzofitimod study in pulmonary sarcoidosis

aTyr Pharma announced FDA alignment on a global Phase 3 protocol for efzofitimod in pulmonary sarcoidosis and plans to start study activities in Q4 2026.Key Highlights:Original SEC Filing: aTYR PHARMA INC [ ATYR ] - 8-K - Sep. 24, 2026This is an AI-powered summary. It may contain inaccuracies. Cons…